Home › Urothelial (Transitional Cell) Carcinoma › Massachusetts
Urothelial (Transitional Cell) Carcinoma clinical trials in Massachusetts
17 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- UMass Memorial Medical Center - University Campus, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- Massachusetts General Brigham, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT07218380Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UMass Memorial Medical Center, Worcester
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06451497Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
Ages 65 and older · All sexes · Updated Feb 17, 2026 · NCT06138561Sacituzumab Govitecan Plus EV in Metastatic UC
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT04724018SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.